Colchicine (Colcrys) is a promising adjunctive option in secondary prevention of cardiovascular events, probably because of its ability to stop or slow neutrophil reaction to intravascular cholesterol crystals.
Investigators recently looked at colchicine’s role in heart disease through a systematic review and meta-analysis of randomized, controlled trials. They searched for trials that randomized adult patients with cardiovascular disease to receive colchicine or either placebo or no therapy.
Colchicine www.raw-pharmaceutical-materials.com/products/Colchicine/ was shown to reduce composite cardiovascular outcomes by 60%. The rates of pericarditis recurrence, post-operative atrial fibrillation, post-pericardiotomy syndrome, and post-cardiac surgery or radiofrequency ablation were nearly halved.